RxDoctor Payments Data

Robert Potts, PA

Physician Assistant · Moundsville, WVNPI 1134294036

Payments from drug & device makers

$1,851in general payments, 2019–2025

Across 28 payments — averaging $66.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$486
  • AbbVie$457
  • AstraZeneca$260
  • Regeneron Healthcare Solutions, Inc.$221
  • Gilead$109
  • Phathom Pharmaceuticals, Inc.$108
  • plus $210 from 3 others

What the payments were for

  • Food & beverage$1,75295%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,851 in reported general payments places this provider in the 85th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$33,020
Medicare patients
292
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide101$77,025
CreonLipase/Protease/Amylase12$16,715
ClenpiqSod Picosulf/Mag Ox/Citric Ac91$15,458
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates166$11,138
Pantoprazole Sodium309$2,737
Colestipol Hcl31$2,675
Balsalazide Disodium24$2,162
Budesonide DrBudesonide12$1,847
Lubiprostone14$1,814
Spironolactone59$1,395
Omeprazole84$1,306
Esomeprazole Magnesium19$668
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl49$648
Famotidine79$595
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl22$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$457$93,740113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Moundsville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →